Physician profile
Stuart Soroka
NPI 1922069707
$8,386.30
in general payments reported to CMS, 2019-2025
34 companies · $1,871 in 2025
The $1,871 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $202 · 2021: $843 · 2022: $1,262 · 2023: $2,068 · 2024: $1,607 · 2025: $1,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,528 · Education: $17.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,527.98 |
| Education | $17.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,299.98 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $1,046.92 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $795.17 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $736.27 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $481.45 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $359.93 | 2021-2024 | Dificid, Zerbaxa, Zinplava |
| Celgene Corporation | $294.73 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $264.42 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $250.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $229.88 | 2019-2025 | |
| Lilly USA, LLC | $201.30 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $170.81 | 2019-2024 | Injectafer |
| Qol Medical, LLC | $155.00 | 2024 | Sucraid |
| Gilead Sciences, INC. | $131.41 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $116.72 | 2022-2024 | Linzess |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $110.77 | 2021-2025 | Ocaliva |
| Braintree Laboratories, INC. | $105.67 | 2020-2024 | Suflave, Sutab |
| Alnylam Pharmaceuticals INC. | $96.60 | 2023-2025 | Givlaari |
| Boston Scientific Corporation | $83.67 | 2021 | |
| Enterra Medical, INC. | $80.50 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $63.38 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $57.35 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $40.86 | 2025 | Zenpep |
| Ardelyx, INC. | $30.06 | 2025 | Ibsrela |
| Amgen INC. | $27.49 | 2022 | |
| Redhill Biopharma INC. | $25.88 | 2021-2022 | |
| Pentax of America, INC. | $19.90 | 2020 | |
| Vivus LLC | $19.11 | 2021 | |
| Celltrion USA INC. | $17.95 | 2024 | Zymfentra |
| Pharming Healthcare, INC. | $17.41 | 2021 | |
| Shionogi INC | $14.84 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.51 | 2024 | Rebyota |
| Alfasigma USA, INC. | $13.16 | 2020 | |
| Nestle Healthcare Nutrition INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Soroka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.